Summary of recommendations {#s1}
==========================

Evidence that serrated lesions (SLs) have premalignant potential

**Statement 1**

Some SSLs have molecular, genetic and pathological features consistent with being precursor lesions to CpG island methylator phenotype (CIMP)+ colorectal cancers (CRCs), which represent 15%--30% of all CRCs (*moderate quality evidence, 100% agreement*).

Pathology and nomenclature of SLs

**Statement 2**

We suggest adopting the terms hyperplastic polyp (HP), SSL, SSL with dysplasia, traditional serrated adenoma (TSA) or mixed polyp to describe SLs in the colorectum, using the WHO criteria to define SSL (*weak recommendation, low quality evidence, 82% agreement*).

Detection and resection of SLs

**Statement 3**

We suggest a minimum withdrawal time of 6 min to enhance SL detection. Chromoendoscopy can also enhance SL detection (*weak recommendation, low quality evidence, 100% agreement*).

**Statement 4**

We recommend that colonoscopy is the best current test for SL detection, with other modalities performing less well (faecal occult blood test (FOBT)/faecal immunochemical test (FIT)±stool DNA, CT colonography (CTC), flexible sigmoidoscopy, capsule colonoscopy) (*strong recommendation, moderate quality evidence*, *100% agreement*).

**Statement 5**

We suggest that endoscopic resection of proximal SSLs, particularly those ≥10 mm in size, should be undertaken by operators who demonstrate achievement of outcomes for incomplete resection rates, serrated polyp detection rates and expertise in assessment of these at colonoscopy (see BSG-Association of Coloproctology of Great Britain and Ireland (ACPGBI) guideline on large non-pedunculated colorectal polyps (LNPCPs) 2015 and statements 13 and 14) (*weak recommendation, low quality evidence, 91% agreement*).

Surveillance strategies after detection of SLs

**Statement 6**

We suggest that given the elevated CRC risk in patients who meet the WHO criteria for serrated polyposis syndrome (SPS), and that effective surveillance appears to reduce CRC risk, these patients should be offered one to two yearly colonoscopic surveillance (*weak recommendation, low quality evidence, 90% agreement*).

**Statement 7**

We suggest that after piecemeal endoscopic mucosal resection (EMR) of a SL ≥20 mm that an examination of the resection site be performed within 2--6 months postresection (*weak recommendation, low quality evidence, 100% agreement*).

**Statement 8**

We suggest that until further evidence on the efficacy or otherwise of surveillance are published, patients with SSLs that appear associated with a higher risk of future neoplasia or CRC (SSLs ≥10 mm or SLs harbouring dysplasia including TSAs) should be offered a one-off colonoscopic surveillance examination at 3 years (*weak recommendation, low quality evidence, 90% agreement*).

**Statement 9**

We suggest that at present for HPs or SSLs \<10 mm in size without dysplasia, there is no clear indication for colonoscopic surveillance unless sufficient in size, location and number to meet the criteria for SPS (*weak recommendation, very low quality evidence, 90% agreement*).

Special situations: SPS

**Statement 10**

We suggest that upper GI surveillance for polyposis or extraluminal surveillance for non-GI cancers is not necessary in patients with SPS where other genetic causes have been excluded (*weak recommendation, very low quality evidence, 100% agreement*).

**Statement 11**

We suggest that all patients with SPS should be referred to clinical genetics services or a polyposis registry, where local resources allow (*w* *eak recommendation, very low quality evidence, 100% agreement*).

**Statement 12**

We suggest that surgery should be considered in patients with SPS who have lesions that are not amenable to colonoscopic resection because of their size, site or number (*weak recommendation, very low quality evidence, 100% agreeent*).

We suggest that surgery should aim to remove all lesions that are not amenable to endoscopic resection, and could take the form of: segmental colectomy, total colectomy with ileorectal anastomosis or proctocolectomy (with or without ileoanal pouch formation) depending on the lesion burden and distribution (*w* *eak recommendation, very low quality evidence, 100% agreement*).

Education, audit and benchmarks and research questions

**Statement 13**

We recommend that clinicians involved in the care of patients with serrated polyps, especially endoscopists and pathologists, acquire the knowledge and skills to recognise and differentiate the various types of SLs (*strong recommendation, moderate quality evidence, 100% agreement*).

**Statement 14**

We suggest that benchmarking SL detection rates is challenging and affected by case mix, patient ethnicity, histopathological diagnosis and the inclusion of distal SLs; however, endoscopists who wish to assess their proximal serrated polyp detection rate might aim for a detection rate \>5% (*w* *eak recommendation, low quality evidence, 88% agreement*).

**Statement 15**

We suggest that the current evidence base for clinical decision making for patients with SLs is poor. Clinicians are strongly advised to support prospective studies that will bolster this evidence and avoid empirical management decisions, to allow formal guidelines to be developed (*w* *eak recommendation, low quality evidence, 100% agreement*).

Background and methodology {#s2}
==========================

This British Society of Gastroenterology (BSG) position statement is the output of a working group convened by the vice presidents for the BSG (Endoscopy section) to provide clinical guidance on the management of patients diagnosed with hyperplastic and serrated polyps. Topics for the review were developed by the multidisciplinary working group including basic scientists (SJL, IT), clinical geneticists (IT), pathologists (ACB, NAS), gastroenterologists (JEE, SD, SNK, PSP, MDR, CJR), colorectal surgeons (SKC) and epidemiologists (WSA). These topics include major clinical issues encountered by clinicians caring for patients with hyperplastic and serrated polyps, as well as audit and benchmarks, education and questions for further research. As the evidence base was not felt to be sufficient for a formal BSG guideline, a position statement was developed, which offers clinical guidance and points the likely direction of thinking of the society, with the position statement being replaced by a formal guideline in due course.

An initial teleconference was used to outline key clinical questions for the group to consider. For each identified question, a member of the working group performed a comprehensive keyword literature search, reviewed and analysed the quality of the evidence and summarised the key points. Where appropriate evidence existed, a 'position statement' was drawn up according to the GRADE recommendations (strong or weak/conditional recommendations; high, moderate, low or very low quality evidence).[@R1] Following each round of electronic voting, statements were adopted using a modified Delphi process when ≥80% of the working group agreed with them. If after two rounds there was continuing disagreement, if 50% of the group agreed and \<20% disagreed, statements were accepted.[@R2] Initial searches were completed in June 2015; during the Delphi process for non-agreed statements that required subsequent rounds, further searches for key papers that might further guide the working group were permitted due to initially poor but rapidly developing evidence base, final search June 2016. The position statement has been reviewed and agreed by the BSG Endoscopy Section Committee and BSG Clinical Standards and Services Committee.

This is not a BSG clinical guideline due to the methodology used; however, it does represent the view of the multidisciplinary expert working group panel, which represent BSG Endoscopy, Pathology and Colorectal sections. The group also includes representatives from NHS Bowel Cancer Screening Programme, Bowel Screening Wales, Scottish Bowel Cancer Screening and Welsh Association for Gastroenterology and Endoscopy, but does not imply endorsement from these groups.

Introduction {#s3}
============

The adenoma-carcinoma sequence describes the sequential accumulation of a series of genetic mutations leading to advanced adenomas and then invasive cancer.[@R3] [@R4] Over the last 30 years, this model has been used as an essential framework to understand the pathogenesis of CRC. More recently, painstaking molecular and phenotypic characterisation of CRC has demonstrated significant pathogenic heterogeneity and the taxonomic subdivision of CRC now necessarily encompasses the tumour precursor lesion and molecular pathogenesis, alongside lesion distribution and morphological phenotype ([figure 1](#GUTJNL2017314005F1){ref-type="fig"}).

![Considering the spectrum of colorectal cancer (CRC)---conventional adenomas progress by the sequential accumulation of genetic mutations and chromosomal instability causing microsatellite stable (MSS) tumours. Microsatellite instability (MSI) is the result of defective DNA repair through inactivation of mismatch repair genes and is epitomised by the germline mutation of Mis-Match Repair (MMR) genes seen in Lynch syndrome (hereditary non-polyposis coli). The sessile serrated neoplasia pathway is often initiated by genetic mutation of *BRAF* or *KRAS* genes but then progresses by methylation of tumour suppressing genes (CpG island methylator phenotype (CIMP)). Both MSS and unstable tumours can result depending on the genes epigenetically silenced as the lesions progress. Comparatively, little is known about the traditional serrated pathway, but evidence is accumulating that this is a distinct molecular subtype.[@R9] FAP, familial adenomatous polyposis.](gutjnl-2017-314005f01){#GUTJNL2017314005F1}

Importantly, these alternative pathways to the conventional adenoma-carcinoma model appear to account for 15%--30% of CRC cases and are significantly over-represented in interval cancers ([figure 1](#GUTJNL2017314005F1){ref-type="fig"}).[@R5] Hyperplastic (serrated) polyps had previously been considered benign and lacking in premalignant potential;[@R8] however, multiple lines of evidence suggested that some subtypes of HP were precursor lesions for cancers of non-adenomatous origin, as part of the 'serrated pathway' to CRC.[@R9] [@R10]

Evidence that SLs have premalignant potential {#s3a}
---------------------------------------------

*Molecular, genetic, pathological and epidemiological*

CpG island methylator phenotype {#s3b}
-------------------------------

Methylation is the addition of a methyl group (CH~3~) to the cytosine nucleotide in a CpG dinucleotide context. Methylation of gene promoters is a physiological mechanism to regulate gene expression without altering the DNA sequence and is thus termed an 'epigenetic' change. When aberrant DNA methylation results in the transcriptional silencing of important tumour suppressor genes, neoplastic growth can be promoted. This aberrant methylation has been called the CIMP and is thought to be important in the serrated pathway. CIMP status can be detected by screening a panel of genes that are known to be particularly susceptible to promoter methylation.[@R10] CIMP+ tumours probably account for a third of all CRCs,[@R9] [@R11] although the prevalence varies considerably depending on the marker panel used, the population being studied and the colonic regional distribution.[@R12]

The serrated neoplasia pathway {#s3c}
------------------------------

SLs of the colorectum are characterised histologically by a saw-toothed appearance of the crypt epithelium. Formerly, all lesions exhibiting this characteristic morphology were called HPs and were thought to have no malignant potential;[@R8] however, more recently SLs have been characterised by their morphological and molecular profiles into different subsets, which vary in their risk of malignant transformation.

### Sessile serrated lesions {#s3c1}

The use of CIMP marker panels provided molecular tools to investigate the precursor lesions of CIMP+ tumours. Many benign sessile serrated polyps (SSPs) are BRAF mutant and are CIMP+,[@R13] and analysis of SSLs with an adjacent region of cancer show shared immunohistochemical and molecular features between the benign and malignant foci.[@R17] Furthermore, case reports describe the development of cancer within serrated polyps that were left in situ and followed-up endoscopically.[@R20] [@R21] This evidence has led to the establishment of a proposed serrated neoplasia pathway, where HPs initiated by *BRAF* or less commonly *KRAS*, mutation proceed to SSLs with the accumulation of epigenetic gene silencing, although it may be that SSLs arise de novo. Inactivation of tumour suppressor genes causes the development of cellular atypia (SSL with dysplasia) with eventual progression to cancer. There is a progressive increase of *BRAF* mutant CIMP+ tumours from the rectum to the caecum[@R22] and the reason behind this proximal predilection is unknown.

### Traditional serrated adenomas {#s3c2}

The pathogenesis of these sporadic lesions is less clear. The serrated phenotype differs from that seen in HP and SSPs, resulting from surface indentations associated with the characteristic ectopic crypt foci that develop orthogonally to the crypt axis.[@R23] Molecular features are not as clearly defined as SSLs, but includes *KRAS* or *BRAF* mutations[@R23] [@R24] along with variable levels of CIMP positivity. Recently, high levels of *GREM1* expression in the epithelium of these lesions have been reported, with the suggestion that they are the sporadic corollary of polyps in hereditary mixed polyposis syndrome.[@R25] Unlike some SSLs, these tumours do not appear to progress through mismatch repair gene methylation and microsatellite instability (MSI).[@R26] [@R27]

The over-representation of MSI[@R28] and CIMP+[@R29] tumours in interval cancers (tumours identified in between endoscopic screening examinations) has led to the suggestion that sessile serrated adenomas (SSA) can progress very rapidly. This may be partly true for SLs that develop a mutator phenotype with the loss of *MLH-1* function but the over-representation in interval tumours is just as likely to be due to the well-described difficulty in endoscopic detection of these lesions.[@R5] [@R30] **Statement 1**Some SSLs have molecular, genetic and pathological features consistent with being precursor lesions to CIMP+ CRCs, which represent 15%--30% of all CRCs (moderate quality evidence, 100% agreement).

Nomenclature and pathological features of SLs {#s4}
=============================================

The nomenclature of SLs is complex as there are differences of opinion between the UK, European and the US pathologists regarding the optimal terminology and the pathological features required to make a diagnosis of an SL ([box 1](#bx1){ref-type="boxed-text"}). We recommend usage of the WHO criteria to diagnose SSL. This means that three crypts---or two adjacent crypts---showing at least one of the features listed in [box 1](#bx1){ref-type="boxed-text"} are required to be present for a diagnosis of SSL. There is no strict 'ranking order' of these features in terms of their importance for the diagnosis and there is also no minimum number of these features that need to be present (apart from the minimum number of characteristic crypts). Box 1Key histological features of sessile serrated lesions (SSLs)▸ Irregular distribution of crypts▸ Dilatation of crypt bases▸ Serration present at crypt bases▸ Branched crypts▸ Horizontal extension of crypt bases\*▸ Dysmaturation of crypts†▸ Herniation of crypts through muscularis mucosa▸ WHO criteria---at least three crypts or at least two *adjacent* crypts must show one or more of these features to enable a diagnosis of SSLs[@R31]▸ American Gastroenterology Association criteria---one crypt showing the characteristic features is sufficient for the diagnosis of SSLs[@R26]\*Involved crypts often have an 'L' or inverted 'T' shape.†Dysmaturation is disordered cellular maturation within crypts and is evidenced by subtle nuclear enlargement, crowding, pseudostratification and mitotic activity together with the presence of a disorganised mixture of non-mucus containing epithelial cells and mature goblet cells within the deep aspects of crypts. In this context, assessment of proliferation index, for example, using MIB-1 may provide supporting evidence for a diagnosis of SSLs by highlighting epithelial cell proliferation within the superficial half of crypts. However, such immunohistochemistry, while sometimes helpful, does not reveal features that are alone diagnostic of SSLs.

In this position statement we have elected to use terminology developed by Bateman and Shepherd, which is approved by the Pathology sections of the BSG and NHS Bowel Cancer Screening Programme. In the USA, the term SSA was originally coined, which encompassed the morphology of these lesions and implied their premalignant nature; however, such lesions do not generally contain 'true' cytological dysplasia.[@R32] WHO proposed the term sessile serrated adenoma/polyp (SSA/P);[@R31] however, again this suggests cytological atypia and many lesions would not meet the pathological definition of being polypoid. Therefore, the UK terminology recommends the term SSL with or without dysplasia. This accounts for the pathology and morphology seen and critically distinguishes lesions, which harbour cytological dysplasia that are thought to be higher risk and on an accelerated pathway to carcinogenesis. The recommended terms for the UK pathological classification of serrated polyps are listed in [box 2](#bx2){ref-type="boxed-text"}. The 'mixed polyp' category was retained for unusual cases, for example, those showing mixed features of SSL and TSA, or polyps thought to represent true 'collision tumours' comprising an adenoma and an HP; however, most polyps showing features of SSL together with one or more areas of dysplasia are likely to represent SSLs in which dysplasia has arisen, rather than 'collision tumours'. Box 2Recommended terminology for (non-invasive) serrated lesions of the colon and rectum▸ Hyperplastic polyp▸ Sessile serrated lesion (SSL)▸ SSL with dysplasia▸ Traditional serrated adenoma▸ Mixed polyp

There are problems of interobserver variability with the pathological reporting of SLs that may in part stem from variations in terminology and diagnostic criteria mainly between HPs an SSLs;[@R30] [@R33] however, this is likely to improve with uniformity of terminology and experience, with one study showing use of a reference article may improve reproducibility.[@R36] TSA show classical cytological dysplasia and distinctive features (eosinophilic cytoplasm, ectopic crypts, pencillate nuclei), and are managed more like classical adenomas.

Readers are directed to the guidance document for a more detailed discussion of the pathological issues (<http://jcp.bmj.com/content/68/8/585.full.pdf+html>).[@R37] **Statement 2**We suggest adopting the terms HP, SSL, SSL with dysplasia, TSA or mixed polyp to describe SLs in the colorectum, using the WHO criteria to define SSL *(weak recommendation, low quality evidence, 82% agreement)*.

Detection and resection of SLs {#s5}
==============================

Detection at colonoscopy {#s5a}
------------------------

### Prevalence {#s5a1}

The prevalence of SLs, and especially SSLs is difficult to determine accurately. The results from the published literature are highly variable, due to inconsistent diagnostic criteria, inappropriate histological classification of different subtypes, variation in polyp detection rates among endoscopists, use of different endoscopic enhancing modalities and population selection criteria. A number of studies have demonstrated that review of polyps previously labelled as hyperplastic results in significant numbers being reclassified as serrated adenomas.[@R30] [@R38] Furthermore, there is substantial interobserver variation even among GI pathologists in diagnosing SSLs.[@R39] Despite these caveats, there is evidence suggesting that SSL detection is improving,[@R41] presumably as a result of either increased recognition by endoscopists and/or pathologists ([table 1](#GUTJNL2017314005TB1){ref-type="table"}).

###### 

Summary of colonoscopic studies evaluating prevalence and detection rates for serrated lesions

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors      Year   Country             Study type      n        Patient population                                                                                           Colonoscopy type          Results\     Results\
                                                                                                                                                                                                          Prevalence   Detection rate
  ------------ ------ ------------------- --------------- -------- ------------------------------------------------------------------------------------------------------------ ------------------------- ------------ -------------------------------------
  Spring       2006   Australia           Prospective     190      All (except FAP, HNPCC, HPS)                                                                                 M, CE                     SL 40%\      
                                                                                                                                                                                                          HP 29%\      
                                                                                                                                                                                                          SSA 9%\      
                                                                                                                                                                                                          TSA 0.7%     

  Hetzel       2010   USA                 Retrospective   7192     Average-risk screening                                                                                       HD                        HP 28%\      SSA-DR 0.6%
                                                                                                                                                                                                          SSA 1.4%     

  Gurudu       2010   USA                 Retrospective   21 238   All                                                                                                          WL                                     SSA-DR 2.9%

  Freedman     2011   USA                 Retrospective   1486     Average-risk screening (\>45 years) or surveillance                                                          WL                        SSP 6.9%     HP-DR 26%\
                                                                                                                                                                                                                       SSP-DR 8%

  Kahi         2011   USA                 Retrospective   6681     Average-risk screening                                                                                       WL                        SL 36%\      PSP-DR 13%
                                                                                                                                                                                                          PSP 11%      

  Rondagh      2011   The Netherlands     Prospective     2309     All (except any hereditary form of CRC, SPS)                                                                 HD, CE                                 SL-DR 13.3%\
                                                                                                                                                                                                                       High-risk SP\*-DR 2.5%\
                                                                                                                                                                                                                       PSP-DR 3.8%

  Buda         2012   Italy               Prospective     985      Average-risk screening                                                                                       HD                        SP 40%\      SL-DR 7.3%\
                                                                                                                                                                                                          HP 26.4%\    HP-DR 4.5%\
                                                                                                                                                                                                          SSL 10.9%\   SSL-DR 2.3%\
                                                                                                                                                                                                          TSA 2.3%     TSA-DR 0.5%

  Leung        2012   China (Hong Kong)   Retrospective   1282     Average-risk screening                                                                                       HD, NBI                                SP-DR 21.4%\
                                                                                                                                                                                                                       SA-DR 0.9%\
                                                                                                                                                                                                                       PSP-DR 7.2%\
                                                                                                                                                                                                                       LSP-DR 2.3%

  Liang        2012   USA                 Retrospective   18 003   All                                                                                                          Assumed WL (no details)                SL-DR 20.6%\
                                                                                                                                                                                                                       (screening only SL-DR 13.9%)

  Min          2012   South Korea         Retrospective   926      Average-risk screening (\>45 years)                                                                          WL                        SP 17.5%     SL-DR 11.9%\
                                                                                                                                                                                                                       PSP-DR 5.3%

  Alvarez      2013   Spain               Prospective     5059     Average-risk screening (50--69 years)                                                                        Assumed WL (no details)                SL-DR 20.8%\
                                                                                                                                                                                                                       PSP-DR 6.5%\
                                                                                                                                                                                                                       LSP-DR 1.8%\
                                                                                                                                                                                                                       SSA+TSA-DR 2.6%

  Anderson     2013   USA                 Retrospective   9100     Average-risk screening and surveillance (all \>50 years, NB poor prep and incomplete colonoscopy excluded)   Assumed WL (no details)                SL-DR† 8% screening\
                                                                                                                                                                                                                       SL-DR† 10% surveillance

  Kumbhari     2013   Australia           Retrospective   1000     All                                                                                                          WL, NBI                                SSA-DR 5.3%\
                                                                                                                                                                                                                       (7% in Caucasians vs 2% in Chinese)

  Lee          2013   South Korea         Retrospective   1375     Average-risk screening (\>50 years)                                                                          HD                        SL 11%\      SL-DR 11.3%\
                                                                                                                                                                                                          PSP 2.7%     PSP-DR 3.1%\
                                                                                                                                                                                                                       High-risk PSP-DR‡ 0.5%

  Raju         2013   USA                 Retrospective   342      Average-risk screening (50--75 years)                                                                        WL§                       SL 11.3%     SL-DR 23%\
                                                                                                                                                                                                                       SSA+TSA-DR 11%

  Hazewinkel   2014   The Netherlands     Prospective     1426     Average-risk screening (50--75 years)                                                                        WL                        SL 41.8%\    SL-DR 27.2%\
                                                                                                                                                                                                          HP 35.5%\    HP-DR 23.8\
                                                                                                                                                                                                          SSA 6.2%\    PSP-DR 12.2%\
                                                                                                                                                                                                          TSA \<0.1%   SSA-DR 4.8%\
                                                                                                                                                                                                                       TSA-DR 0.1%

  Payne        2014   USA and Germany     Retrospective   7215     Average-risk screening (\>50 years)                                                                          Assumed WL (no details)   SL¶ 6.1%     SL-DR 4%\
                                                                                                                                                                                                                       PSL-DR 2.8%
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Dysplastic serrated polyps or large (≥6 mm) proximal non-dysplastic serrated polyps.

†HPs proximal to sigmoid colon plus all SSPs serrated adenomas.

‡Dysplastic PSP or large (\<1 cm).

§Plus lesion-recognition training, cap-fitted colonoscopy, rigorous cleansing and intensive inspection.

¶SSA/P or HPs \>1 cm in proximal colon.

CE, chromoendoscopy; CRC, colorectal cancer; FAP, familial adenomatous polyposis; HD, high definition; HNPCC, hereditary non-polyposis colorectal cancer; HP, hyperplastic polyp; LSP, large (\>1 cm) serrated polyp; M, magnification; NBI, narrow band imaging; PSP, proximal serrated polyp; S/HPS, serrated/hyperplastic polyposis syndrome; SA, serrated adenoma; SP, serrated polyp; SPS, serrated polyposis syndrome; SSA, sessile serrated adenoma; SSL, sessile serrated lesion; SSP, sessile serrated polyp; TSA, traditional serrated adenoma; WL, standard white light.

The prevalence of SLs based on autopsy studies has been reported as between 13% and 35%,[@R42] with these lesions accounting for 27%--51% of all colorectal polyps.[@R42] [@R43] More recent pathology series have demonstrated that the most common SL encountered is the HP, accounting for 24%--42% of all resected colorectal polyps and 83%--96% of all SLs; SSLs represent 2%--4% of all polyps and 3%--11% of SLs. TSAs are much less common, generally accounting for \<1% of all polyps and 1%--7% of SLs.[@R46]

The distribution of SLs varies with the type: HPs and TSAs are usually found in the left colon, while SSLs occur more often in the proximal colon.[@R46] The published literature on colonoscopic detection of SLs is summarised in [table 1](#GUTJNL2017314005TB1){ref-type="table"}. The studies have mostly been retrospective and have varied in the patient population, details of the colonoscopy procedure and reporting of the results. Excluding those studies that have investigated patients with MutYH-associated polyposis (MAP) or SPS, the majority of the evidence relates to average-risk screening patients. Overall, SLs account for 11%--53% of all polyps detected at colonoscopy in screening populations,[@R41] [@R50] SSLs for 1%--13%[@R41] [@R50] [@R52] [@R57] and TSAs for 0.1%--1.9%.[@R50] [@R52] Spring *et al* reported SL prevalence results for an unselected population (ie, symptomatic as well as screening patients), with SLs overall accounting for 40% of all polyps, SSLs for 9% and TSAs for \<1%. Many patients will have more than one serrated polyp present; Álavrez *et al* reported that the mean number of serrated polyps detected was 2, with a range of 1--25.

Endoscopic appearance of SLs {#s5b}
----------------------------

Endoscopically, HPs tend to be diminutive (\<5 mm), pale, sessile[@R45] and have a type II asteroid, stellate or papillary Kudo pit pattern when examined with chromoendoscopy or narrow-band imaging.[@R58] The endoscopic features of SSLs include sessile or flat morphology[@R59] [@R60] with proximal SSLs more likely to be flat than distal lesions,[@R61] a resemblance to prominent folds,[@R60] pale colour,[@R59] indistinct borders[@R62] and mucus capping.[@R60] In 52% of SSLs, a rim of bubbles or debris is present that can help delineate the lesions and serve as an identification aid.[@R60] Additional features on narrow band imaging (NBI) include a cloud-like surface, an irregular shape and dark spots inside the crypts.[@R62] SSLs typically have a type II-O or open Kudo pit pattern on a magnified view; several studies have reported this pit pattern has good sensitivity (84%--97%) and specificity (66%--86%) for identifying SSLs.[@R62] TSAs tend to be protuberant and/or pedunculated, with a type IV (pinecone-like or fern-like) pit pattern.[@R50] [@R65] In a prospective study, Rondagh *et al* [@R66] demonstrated the proximal serrated polyps (PSPs) were more likely to be sessile and less likely to be diminutive compared with distally located lesions.

Colonoscopy for SL detection {#s5c}
----------------------------

There have been few studies which have focussed directly on colonoscopic detection of SLs. Most data are drawn from studies where SLs were detected incidentally and adenomas were the primary end point, and many predate accurate pathological distinction of SLs. Hence, data are not as robust as for adenoma detection rates (ADRs). Furthermore, there is no clear correlation between SL detection rates and interval cancer, unlike that seen for ADRs. Interval cancers are over-represented in the serrated pathway and higher 'polyp' detection rates have been shown to be protective for right-sided CRCs.[@R67] It is possible therefore that improvements in SL detection rates might have a greater impact on interval cancer rates than improvements in ADR, although ADR and SL detection show some correlation (see benchmarks). Summary data on interventions which may or may not improve SL detection are presented in [table 2](#GUTJNL2017314005TB2){ref-type="table"}.

###### 

Interventions at colonoscopy which may improve serrated lesion detection rates (adapted from East *et al* [@R68])

  Beneficial                               May be beneficial                No clear benefit
  ---------------------------------------- -------------------------------- ------------------------------------------------------
  Slower withdrawal \>6 min[@R69] [@R70]   High definition[@R69]            Narrowed spectrum endoscopy (NBI, FICE, iSCAN)[@R71]
  Chromoendoscopy[@R5] [@R72] [@R73]       Right colon retroflexion[@R74]   Antispasmodics[@R75]
                                                                            Good vs adequate bowel preparation[@R69] [@R76]
                                                                            Wide angle and enhanced mucosal views[@R77]

FICE, flexible spectral imaging colour enhancement; NBI, narrow band imaging.

### Withdrawal time {#s5c1}

In a Dutch screening cohort, longer withdrawal time had an OR of 1.12 for detection of SLs.[@R69] Analysis of data from the New Hampshire colonoscopy registry reported an incidence rate ratio of 1.77 for each minute beyond 6 min withdrawal time to a maximum at 9 min.[@R70] In both cases, similar improvements were seen for ADRs.

### Chromoendoscopy {#s5c2}

Chromoendoscopy consistently improves adenomatous as well as non-adenomatous polyps detection rates, with the vast majority of the latter being SLs. A summary of four studies performed between 2002 and 2006, reported an increase in hyperplastic or non-adenomatous polyp detection from 23% to 45% overall, and from 9% to 16% in the proximal colon.[@R5] More recent studies have confirmed this result and effect size in multicentre studies from Germany (46.2% vs 29.5% SLs, rectum excluded)[@R73] and the USA (high-definition colonoscopes; mean non-neoplastic lesions per patient 1.8 vs 1.0).[@R72] All studies used indigocarmine dye as a surface contrast agent. The use of chromoendoscopy to increase yield of serrated polyps in the right colon is currently being trialled in an FOBT-positive screening population in Wales (Contrast Enhanced Colonoscopy (CONSCOP) study; ClinicalTrials.gov identifier: NCT01972451).

### High definition {#s5c3}

In a small single-centre cohort study, detection rates for proximal HPs and for large (≥10 mm) HPs were not different.[@R80] In a Dutch screening cohort, use of high-definition colonoscopes did not improve PSP detection, multivariate ORs 1.07.[@R69] High-definition compared with standard-definition colonoscopy provided only a marginal incremental yield in polyp detection rates of 3.8% (95% CI 1% to 6.7%) in a meta-analysis suggesting that any benefit seen may be small.[@R81]

### Proximal colon retroflexion {#s5c4}

Proximal colon retroflexion showed a modest increase in proximal SL detection, although this gain might have been achieved with a repeated examination in the forward view.[@R74]

### Narrowed spectrum endoscopy {#s5c5}

NBI showed improved detection in a single-centre, single-operator study for detection of SLs in the setting of SPS;[@R82] however, a multicentre study from the same group did not confirm this.[@R83] Four different meta-analyses of NBI versus white light, including more than 3000 patients, failed to show improvements in adenoma or polyp detection rates, suggesting a benefit for serrated polyps is unlikely.[@R71] Similarly, there is no clear detection benefit for either flexible spectral imaging colour enhancement (Fujinon)[@R84] or iSCAN (Pentax) with tone enhancement.[@R87]

Recent data from the new generation of brighter NBI systems (Excera III, Olympus) in a large study looking specifically at SLs detection rates in the proximal colon did not show an overall benefit in the number of proximal SLs detected, but did show a significant benefit for larger SLs.[@R90] Underwater endoscopy has been proposed to improve ADRs. Data for SL are limited but in one study combining two randomised controlled trials there was no overall benefit in proximal SL detection rate of 6% vs 12%.[@R91]

### Antispasmodics {#s5c6}

Hyoscine butylbromide (Buscopan) increased polyp detection in the right colon, 0.43 vs 0.31, p=0.01 in one randomised controlled trial;[@R92] however, a meta-analysis that included this study found no increase in polyp detection rate overall (OR 1.09, 95% CI 0.91 to 1.31).[@R75]

### Bowel preparation {#s5c7}

Few studies have had detection of SLs as a primary outcome. In a Dutch screening study, quality of bowel preparation was not associated with lower proximal SL detection rates, multivariate OR 0.98 (95% CI 0.92 to 1.05).[@R69] In a US registry-based study, serrated polyp detection rates were similar for optimal (excellent or good) versus fair bowel preparation, with an OR of 0.75 (95% CI 0.31 to 1.80) for poor prep versus optimal prep for PSP detection.[@R76] This effect may result from a thicker mucus cap on SLs with lower preparation quality assisting detection.

### Wide angle and enhanced mucosal views {#s5c8}

In a tandem study, the Third Eye Retroscope detected 77 vs 58 non-adenomatous polyps, but in the right colon this was only 19 vs 22 non-adenomatous polyps, so better detection of clinically relevant SLs was not demonstrated.[@R77] Other novel devices to reveal more mucosa have been recently reported such as G-Eye, Full Spectrum Endoscopy and Third Eye Panoramic Device;[@R78] [@R79] however, no current studies report data that allow assessment of proximal SL detection rates. Data for SLs are not yet reported for SL detection rates for other devices, which may improve mucosal visualisation, for example, Endocuff, Endorings. **Statement 3**We suggest a minimum withdrawal time of 6 min to enhance SL detection. Chromoendoscopy can also enhance SL detection (*weak recommendation, low quality evidence, 100% agreement*).

Detection by other modalities {#s5d}
-----------------------------

Although colonoscopic detection of SLs may not be perfect, at present there is not enough evidence to suggest that colonoscopy can be replaced by alternative technologies. CTC has difficulty detecting flat and sessile lesions. The limited published data on the detection of lesions other than conventional adenomas by CTC suggest that this technique lacks adequate sensitivity.[@R93] However, one recent study of flat colonic lesions has suggested that serrated and HPs are more likely to coat with oral contrast than adenomatous polyps, and this may represent a way forward in CTC identification of SLs.[@R94]

### Stool markers {#s5d1}

The potential role of FIT in detecting SLs has been evaluated in a recent study by Heigh *et al*; however, the results were poor at both 50 and 100 ng/mL cut-off values. This is probably because SLs are less likely to bleed than conventional adenomas.[@R95]

Stool DNA tests may offer the ability to detect SLs non-invasively. In a prospective study of 456 screening/surveillance patients, Heigh *et al* [@R96] demonstrated that *mBMP3* proved highly discriminant for detection of SSLs \>1 cm in size. Lidgard *et al* [@R97] evaluated the clinical performance of an automated stool DNA assay in a blinded, case-control study. Stool samples were analysed from 459 screening/surveillance patients and from 544 symptomatic patients, including 30 patients with SSAs. The stool DNA assay measured β-actin (a marker of total human DNA), mutant *KRAS*, aberrantly methylated *BMP3* and *NDRG4* and faecal haemoglobin. Its sensitivity for SSA \>1 cm was 60%.

In a recent large study in an average-risk cohort by Imperiale *et al* [@R98] using FIT versus FIT plus multitarget stool DNA testing, FIT plus DNA significantly outperformed FIT alone for the detection of serrated polyps 1 cm or more in size, 42.4% vs 5.1%, respectively, p\<0.001.

Colon capsule data are limited, especially for reporting of serrated polyps; however, in the largest study reported the serrated polyp detection rate by capsule colonoscopy was up to a third less than by colonoscopy.[@R99] **Statement 4**We recommend that colonoscopy is the best current test for SL detection, with other modalities performing less well (FOBT/FIT±stool DNA, CTC, flexible sigmoidoscopy, capsule colonoscopy) (*strong recommendation, moderate quality evidence, 100% agreement*).

Resection {#s5e}
---------

There has been concern in the gastroenterological community that the risk of trying to resect SLs might potentially outweigh the reduction on CRC risk, especially for larger lesions in the right colon,[@R100] mainly on the basis of data from a large German study of postpolypectomy complications pre-2005.[@R101] For smaller SLs \<10 mm in size standard polypectomy techniques can be applied, although the flat morphology of the lesions can make them difficult to grip. Use of a stiff snare and submucosal lifting may help in these situations. For lesions in the proximal colon cold snaring is preferred.

We suggest that resection of large proximal SSPs is optimally dealt with by individuals and centres with expertise in recognition, detailed assessment and therapy of these lesions. This recommendation is based on the higher risk of incomplete resection and complications associated with removal of large sessile polyps in the right colon and some evidence of a favourable effect of a threshold volume for better outcomes.[@R102] These data, combined with variability in SL detection and assessment (see statements 13 and 14), and data on comparing the similar outcomes on safety of endoscopic resection in adenomas and SSLs,[@R105] suggest a significant role for operator variability and outcomes in the management of these lesions. Therefore, for larger lesions ≥10 mm endoscopists should meet the competencies and standards set out in the BSG 2015 guidelines on management of large non-polypoid colorectal polyps.[@R104]

Specific variations in technique such as underwater EMR,[@R106] use of suction to create pseudopolyps[@R107] and use of specific snares have been proposed as being of help but cannot be recommended at present as being significantly better than standard EMR technique to remove these lesions.[@R108] There is some evidence to suggest that use of a microprocessor controlled diathermy unit, care with use of excessive diathermy and achieving complete endoscopic resection in the first attempt may help to reduce the incidence of complications and recurrence of these lesions.[@R109] [@R110] **Statement 5**We suggest that endoscopic resection of proximal SSLs, particularly those ≥10 mm in size, should be undertaken by operators who demonstrate achievement of outcomes for incomplete resection rates, serrated polyp detection rates and expertise in assessment of these at colonoscopy (see BSG-ACPGBI guideline on LNPCPs 2015, and statements 13 and 14) (*weak recommendation, low quality evidence, 91% agreement*).

Surveillance strategies after detection of SLs {#s6}
==============================================

Data to guide surveillance strategy after detection of SLs are limited with essentially no high-quality prospective data available or likely to be available in the next few years.

High-risk situations {#s6a}
--------------------

SPS (see the 'Serrated polyposis syndrome' section) appears to lead to a substantial future risk of CRC that can be reduced, at least over 5 years, by intensive colonoscopic surveillance. The US multisociety taskforce guidelines have suggested surveillance at one yearly intervals may be appropriate,[@R111] although data on the effectiveness of yearly surveillance and possibly lower risks estimates of future cancer during surveillance were not available to these guidelines groups (see the 'Serrated polyps in colitis' section). Risk estimates do not seem to exceed those for Lynch syndrome and molecular mechanisms to CRC such as loss of DNA mismatch repair may be shared. Therefore, once all larger polyp have been removed, with only polyps 5 mm or less remaining, surveillance can be initiated every 1--2 years (see [figure 2](#GUTJNL2017314005F2){ref-type="fig"}), with the later interval appropriate for those not developing further polyps rapidly once the colon has been cleared, see Hassan *et al* [@R112] for suggested algorithm flow chart. Patients who are first-degree relatives of patients with SPS with at last one PSP (WHO criteria 2), but not meeting the WHO criteria 1 or 3 (see [box 3](#bx3){ref-type="boxed-text"}) may be at lower risk.[@R113] **Statement 6**We suggest that given the elevated CRC risk in patients who meet the WHO criteria for SPS, and that effective surveillance appears to reduce CRC risk, these patients should be offered one to two yearly colonoscopic surveillance (*weak recommendation, low quality evidence, 90% agreement*). Box 3WHO definition of serrated polyposis syndrome 2010[@R31]\*1. At least five serrated polyps proximal to the sigmoid colon, two of which are \>10 mm in diameter2. Any number of serrated polyps occurring proximal to the sigmoid colon in an individual who has a first-degree relative with serrated polyposis3. More than 20 serrated polyps of any size distributed throughout the colon\*Serrated lesion refers to any combination of hyperplastic polyps and sessile serrated polyps.

![Serrated surveillance flow chart.](gutjnl-2017-314005f02){#GUTJNL2017314005F2}

There are data from clinical studies in adenomatous polyps that piecemeal resection increases the risk of lesion recurrence,[@R114] with epidemiological data pointing to a risk of interval cancer from partly resected SLs. The CARE study suggested that rates of residual lesion are much higher for SLs than for adenomas.[@R103] Therefore, it is logical that the same guidance after piecemeal resection of adenomas should apply to piecemeal resection of serrated polyps, that is, a site check at 2--6 months for lesions 20 mm or greater in size. This is consistent with the BSG 2015 guideline on management of large LNPCPs.[@R104] This guideline also suggests that where possible polyps \<20 mm in size be resected en bloc; however, this may be a particular challenge for SL in the right colon. Therefore, if SLs between 10 and 20 mm are resected piecemeal it may be left to the endoscopist discretion as to whether a site check is required at 2--6 months or whether standard surveillance intervals can be applied (see statement 8), depending on patient factors and assessment of likelihood of complete excision. Recent data from a large series in Australia suggest that the recurrence rate for SSPs ≥20 mm resected with piecemeal EMR is lower than for adenomas but still significant, 7% vs 20% at 12 months.[@R105] **Statement 7**We suggest that after piecemeal EMR of a SL ≥20 mm that an examination of the resection site be performed within 2--6 months postresection (weak recommendation, low quality evidence, 100% agreement).

Moderate risk situations {#s6b}
------------------------

The presence of sporadic SSA/Ps may represent an mucosal field defect with detection of one SSA/P making detection of synchronous SSA/P[@R115] as well as metachronous SSA/P during surveillance more likely.[@R118] [@R119] There is evidence they are also associated with neoplasia. Patients with baseline advanced adenomas and proximal SSA/P were more likely to have advanced neoplasia detected at follow-up, however, this was not the case for baseline tubular adenomas.[@R120] In addition, a retrospective study found that 15% of patients with SSA/P at baseline endoscopy had advanced neoplasia over an 8.3-year follow-up.[@R115]

### Higher risk lesions {#s6b1}

There is evidence that larger SSA/Ps (≥ 10 mm) are predictive of advanced neoplasia[@R51] [@R52] [@R120] with a number of studies demonstrating that this association is synchronous.[@R50] [@R120] [@R125] Furthermore, increasing size of SSA/P has been associated with dysplasia and found to be predictive of CRC.[@R122] [@R123] [@R126] SSA/P prevalence as well as the presence of dysplasia is associated with increasing age,[@R126] [@R127] but the risk and rate of progression of SSA/P to dysplasia and cancer has not been clearly delineated. However, a mean progression interval of 15 years from SSA/P without cytological dysplasia to cancer has been suggested.[@R48]

There is discrepancy in the reported risk of metachronous CRC in the setting of SSA/P. Some studies have found that there is no evidence of increased risk of metachronous CRC.[@R51] [@R118] [@R119] However, a recent study found an HR for CRC of 2.5 (95% CI 0.8 to 7.8) in individuals with large serrated polyps, equivalent to that of advanced adenomas.[@R123] Other studies also support SSA/P as an independent risk factor for CRC, with incidence significantly higher in patients with SSA than control patients with hyperplastic and adenomatous polyps.[@R115] A large Danish population-based study has recently suggested that SSA/Ps are risk equivalent to adenomas in terms of future long-term CRC risk, with SSPs with dysplasia and TSAs being particularly high risk[@R128] (see [figure 2](#GUTJNL2017314005F2){ref-type="fig"}).

The US Multi-Society Task Force on CRC guidelines from 2012 and the European Society of GI Endoscopy polyp surveillance guidelines from 2013 both recommend a surveillance examination at 3 years for patients with a single SSP ≥10 mm in size.[@R111] [@R129] **Statement 8**We suggest that until further evidence on the efficacy or otherwise of surveillance are published, patients with SSLs that appear associated with a higher risk of future neoplasia or CRC (SSLs ≥10 mm or SLs harbouring dysplasia including TSAs) should be offered a one-off colonoscopic surveillance examination at 3 years (*weak recommendation, low quality evidence, 90% agreement*).

### Lower risk lesions {#s6b2}

Diminutive HPs in the rectosigmoid are not thought to be risk markers for future CRC risk. Whether one or two proximal small or diminutive HPs or SSLs are risk markers for future CRC is unclear, with studies reporting risk showing most risk is associated with larger lesions (see High risk lesions). Pathological distinction of HPs and SSLs also becomes more challenging as lesion size decreases. Similar to data for adenomas, the number of SSA/P has also been implicated in a retrospective study where three or more serrated polyps were an independent predictor of synchronous advanced neoplasia.[@R121] Overall, data are limited to support any significant excess risk of small SSA/P. Multiple serrated polyps \<10 mm in size, especially in a young patient, might represent an incomplete phenotypic expression of SPS and therefore surveillance in this setting needs to be individualised to the size, location and pathology of the lesions in an individual patient (see [figure 2](#GUTJNL2017314005F2){ref-type="fig"}). **Statement 9**We suggest that at present for HPs or SSLs \<10 mm in size without dysplasia there is no clear indication for colonoscopic surveillance unless sufficient in size, location and number to meet the criteria for SPS (*weak recommendation, very low quality evidence, 90% agreement*).

### Other considerations {#s6b3}

There are no data on longitudinal risk after polypectomy, however, one study has demonstrated 47% of large SSA/P that underwent polypectomy were incompletely removed.[@R103] There are multiple case reports describing carcinomas arising from SSA/P,[@R20] [@R21] [@R130] and interval cancers are more likely to be derived from the serrated pathway.[@R133] However, in a study where 23 large serrated polyps were left in situ for a median of 11.0 years, none of these developed malignant tumour.[@R123]

Special situations: SPS and serrated polyps in colitis {#s7}
======================================================

Serrated polyposis syndrome {#s7a}
---------------------------

Serrated polyps can be multiple and if present in sufficient numbers and size can meet the criteria for SPS (previously called HP syndrome; WHO definition, [box 3](#bx3){ref-type="boxed-text"}).

Estimates of the prevalence of SPS in the population have traditionally been very low, with figures of 1:100 000 quoted; however, in screening populations the prevalence may be higher. In FOBT-based screening, the prevalence of SPS may exceed 1:300, although the rate in colonoscopy-based programmes is approximately 1:2000, making this an important syndrome for screening colonoscopists to recognise in these programmes ([table 3)](#GUTJNL2017314005TB3){ref-type="table"}.[@R134]

###### 

Serrated polyposis syndrome prevalence in population-based screening by modality (adapted from East *et al* [@R68])

  Author     Screening modality       n/pop       \% (95% CI)             Ratio
  ---------- ------------------------ ----------- ----------------------- --------
  Lockett    Flexible sigmoidoscopy   12/40 674   0.029% (0.02 to 0.05)   1:3000
  Orlowska   Colonoscopy              28/50 148   0.056% (0.04 to 0.09)   1:1791
  Kahi       Colonoscopy              3/6681      0.04% (0.01 to 0.014)   1:2227
  Biswas     FOBT (guaiac)            5/755       0.66% (0.24 to 1.52)    1:151
  Moreira    FOBT (FIT)               8/2355      0.34% (0.17 to 0.67)    1:294

FOBT, faecal occult blood test; FIT, faecal immunochemical test.

SPS was originally described to avoid misclassification as familial adenomatous polyposis (FAP), and was not thought to confer any increased risk of CRC;[@R139] however, this was challenged in 1996 where a case series of CRC associated with SPS was described.[@R32] Subsequent larger recent series from the Netherlands and the USA have confirmed an increased risk of CRC during colonoscopic surveillance of 7% at 5 years and two cancers in 44 patients over 2 years,[@R140] [@R141] although these estimates may be inflated by ascertainment bias, and a recent large international multicentre series reported a lower rate of 1.9 events/1000 person-years surveillance (95% CI 0.3 to 6.4).[@R142] A multicentre Spanish series also reported a lower than previously reported risk, 1.9% CRC risk at 5 years.[@R143]

In a series from the same group in the Netherlands and from an international cohort the risk of CRC in first-degree relative was five times that of the general population.[@R144] In common with other colonic polyposis, there has been consideration of whether extracolonic GI polyposis (upper GI tract of small bowel) exists, with none reported,[@R141] or whether there might be an association with extracolonic cancers. No report confirms an association with extracolonic carcinoma; however, one report indicated an association with pancreatic carcinoma in first-degree relatives of patients with SPS, which has not been supported in another case series.[@R145] [@R146] **Statement 10**We suggest that upper GI surveillance for polyposis or extraluminal surveillance for non-GI cancers is not necessary in patients with SPS where other genetic causes have been excluded (*weak recommendation, very low quality evidence, 100% agreement*).

Given the multiple polyps, high risk of CRC, evidence of familial clustering, associated family history of CRC in 50% of cases and increased risk of CRC in first-degree relatives, there has been a concerted effort to find a genetic cause for SPS. Genes (and associated syndromes) associated with an SPS phenotype include: *MUTYH* (MAP); *BMPR1A* (juvenile polyposis syndrome);[@R147] *SMAD4* (juvenile polyposis syndrome);[@R148] [@R149] *PTEN* (Cowden syndrome[@R150]); *GREM1* (hereditary mixed polyposis syndrome[@R151]); *RNF43* (multiple serrated polyps[@R152]). However, no genetic mutation is identified for the majority of cases. In a series of 65 individuals fulfilling the WHO criterion 1 or 3, systematically investigated for mutations in these genes, no significant abnormalities were found.[@R153] Thus, while determining whether an individual fulfils the WHO definition of SPS is relatively straightforward; the phenotypic overlap with other syndromes is an important potential pitfall. We therefore recommend that all patients with a clinical diagnosis of SPS are referred to a clinical genetics unit or dedicated polyposis registry to ensure that an alternative diagnosis is not missed.

In addition, centralisation of individuals and families into such units allows appropriate recall for surveillance, identification of relatives who should also have surveillance and facilitates research into SPS and its underlying genetics. **Statement 11**We suggest that all patients with SPS should be referred to clinical genetics services or a polyposis registry, where local resources allow (*weak recommendation, very low quality evidence, 100% agreement*).

On the same basis as other polyposis syndrome, for example, attenuated FAP, endoscopic management may be appropriate if the size, location and number of polyps are manageable, the patient is willing and the appropriate endoscopic skill set is available (usually tertiary centres). A recent series for Amsterdam suggests that once the colon is cleared relatively few patients (3/41) need surgery during 5 years of intensive surveillance with no cancer developing[@R154] (for position statement see the 'Surveillance strategies after detection of SLs' section). **Statement (repeated from surveillance section) 6**We suggest that given the elevated CRC risk in patients who meet the WHO criteria for SPS, and that effective surveillance appears to reduce CRC risk, these patients should be offered one to two yearly colonoscopic surveillance (*weak recommendation, low quality evidence, 90% agreement*).

However, in the same series 26 of 78 inception patients came to surgery for cancer at presentation, extensive polyposis or high risk or unresectable polyps.[@R154] As with other polyposis syndromes therefore, surgical resection should be seriously considered when colonoscopic removal of polyps is not feasible, in order to reduce cancer risk.[@R155] These surgical principles apply when cancer is detected in the context of SPS. **Statement 12**We suggest that surgery should be considered in patients with SPS who have lesions that are not amenable to colonoscopic resection because of their size, site or number (*weak recommendation, very low quality evidence, 100% agreement*).We suggest that surgery should aim to remove all lesions that are not amenable to endoscopic resection, and could take the form of: segmental colectomy, total colectomy with ileorectal anastomosis or proctocolectomy (with or without ileoanal pouch formation) depending on the lesion burden and distribution (*weak recommendation, very low quality evidence, 100% agreement*).

Serrated polyps in colitis {#s7b}
--------------------------

Patients with longstanding extensive colitis have an increased risk of developing CRC. Although many colitis-associated cancers may develop from sporadic adenomas (the adenoma-carcinoma sequence), it is recognised that a proportion of cancers in patients with colitis arise from an inflammation-cancer pathway involving a different frequency, sequence and timing of molecular events (eg, earlier loss of *Adenomatous Polyposis Coli (APC)* function and later *p53* mutation) compared with sporadic, non-IBD-related carcinogenesis. Very little consideration has been given to the possibility of a serrated dysplasia pathway for inflammation-driven carcinogenesis in colitis.

### Incidence {#s7b1}

Serrated polyps do occur in IBD; however, the incidence of SLs in patients with colitis is unknown. Historical studies may be unreliable, due to under-reporting of a lesion that was previously believed to be of no clinical significance and the lesions may be even more difficult to identify in inflamed mucosa.

Several studies have reviewed pathology specimens to determine the incidence of serrated histology in colitis-associated neoplasia. Bossard *et al* [@R156] reported that serrated preneoplastic lesions accounted for 6.9% (2/29) of all preneoplastic lesions in inflamed IBD mucosa, a lower proportion than that seen in patients without IBD, although this may be due to sample size. Rubio compared the histological phenotypes of neoplasia in 96 colectomy specimens in patients with colitic cancer.[@R157] In colitis, a dysplastic serrated pattern occurred in 12% of the neoplasia in circumscribed Dysplasia Associated Lesion or Mass (DALM)-type lesions and in 29% of the adenomatous (Adenoma Like Mass (ALM)) lesions with well-defined borders surrounded by non-dysplastic colorectal mucosa; however, the invading cancer phenotype was serrated in only in 4% of the colitic cancers . In an earlier study by Rubio *et al*,[@R158] the histological phenotype of dysplasia adjacent to CRCs was assessed in 50 IBD and 50 non-IBD colectomy specimens. Serrated neoplasia accounted for 28.9% (11 out of 38) of the non-invasive dysplastic lesions abutting IBD carcinomas but only 3.4% (1 out of 29) of control specimens. Aust *et al* [@R159] demonstrated activating *BRAF* mutations typical of SSPs were identified in 9% (3 out of 33) of colitis-associated cancers, consistent with the hypothesis that some colitis-associated cancers may arise through the serrated pathway.

### Different pathways to neoplasia {#s7b2}

As described above, it is clear that some cancers in colitis have associated serrated histopathology; what is unknown is whether this serrated pathway is promoted by colitic inflammation or coincidental to it. Several studies paint a rather mixed picture. Odze *et al* [@R160] found no significant difference in the prevalence of *KRAS* mutations, loss of heterozygosity of *APC*, *3p*, *p53* or *p16*, between chronic UC-associated HPs (not SSPs per se), sporadic HPs and inflamed colitic mucosa. Srivastava *et al* [@R161] reported three patients with longstanding IBD who developed numerous hyperplastic/serrated colonic polyps similar to those described in the SPS. Two patients had CRC. KRAS mutation was detected in 45% (5/11) polyps and the mucinous adenocarcinoma, more than expected for the standard serrated pathway. Moreover, *BRAF* mutations were not identified in any of the serrated polyps tested, raising the possibility of a separate IBD-serrated pathway. Bossard *et al* [@R156] retrospectively reviewed neoplastic lesions from 36 patients with IBD. These included one HP and one TSA, both of which exhibited the V600E *BRAF* mutation without MSI or MMR deficiency. The TSA was close to a mucinous adenocarcinoma, which exhibited the *BRAF* mutation and MSI with loss of hMLH1. This is consistent with the sequence of molecular events described in the serrated pathway.

*KRAS* mutations are uncommon in the serrated pathway, but are observed preferentially in sporadic colorectal carcinogenesis. *KRAS* activating mutations occur very early in IBD-related carcinogenesis, as evidenced by *KRAS* mutations being detected in control inflammatory non-dysplastic mucosa.[@R156] This suggests that the serrated pathway is distinct from the inflammation-cancer pathway and that thus far there is no clear evidence to suggest that SLs seen in colitis are more common that might be seen sporadically. Therefore, there may be no specific colitis-associated SL, in contrast to the accepted concept of colitis-associated dysplasia/cancer. The strength of the data available means no statement on SLs in colitis was felt to be appropriate at this time.

Education, audit and benchmarks and research questions {#s8}
======================================================

Pathological and endoscopic images of SLs {#s8a}
-----------------------------------------

Video demonstration of technique for en bloc hot snare EMR of a 12 mm right-sided SSL: <https://www.youtube.com/watch?v=Z_GKfMmRve0>. **Statement 13**We recommend that clinicians involved in the care of patients with serrated polyps, especially endoscopists and pathologists, acquire the knowledge and skills to recognise and differentiate the various types of SLs (*strong recommendation, moderate quality evidence, 100% agreement*).

Given the accepted importance of the serrated pathway in clinical practise for gastroenterologists, surgeons and pathologists, we would recommend that knowledge in these areas be incorporated into the new national gastroenterology curriculum for higher training ([figures 3](#GUTJNL2017314005F3){ref-type="fig"}A--D and [4](#GUTJNL2017314005F4){ref-type="fig"}A--D).

![(A) A 15 mm sessile serrated lesion without dysplasia in the right colon. Note the adherent mucus cap which aids detection. (B) The same lesion after washing and application of indigocarmine dye-spray to clarify lesion boarders and extent. (C) Lesion lifted with dilute methylene blue in lifting solution providing contrasting background to aid precise resection. (D) Postpolypectomy defect after cold snare piecemeal endoscopic mucosal resection.](gutjnl-2017-314005f03){#GUTJNL2017314005F3}

![(A) A microvesicular hyperplastic polyp showing serration within the upper half of the lesion and with none of the characteristic features of a sessile serrated lesion (SSL) (magnification ×100). (B) An SSL showing pronounced serration at the crypt base and horizontal spreading of a crypt, forming a typical 'L' or 'boot' shape (magnification ×200). (C) An SSL showing a sharp distinction between areas showing no dysplasia and low-grade dysplasia (magnification ×100). (D) A traditional serrated adenoma (TSA) showing a pronounced villous growth pattern, pencillate nuclei, eosinophilic cytoplasm and ectopic crypt foci (magnification ×200). (Reproduced from Bateman and Shepherd,[@R37] with permission from BMJ Publishing Group.)](gutjnl-2017-314005f04){#GUTJNL2017314005F4}

Audit and benchmarks {#s8b}
--------------------

The ADR is now an accepted quality marker for colonoscopy, for both general (BSG Quality and Safety indicators) and for screening colonoscopy.[@R162] There is some evidence that the ADR correlates with SSL-DR[@R41] and proximal SL-DR[@R69] [@R135]

The overall detection rates for SLs (ie, percentage of colonoscopes with ≥1 such lesion) have been reported as 4%--35% in average-risk screening populations,[@R35] [@R50] [@R55] [@R163] 13%--21%[@R125] [@R165] in unselected populations (ie, symptomatic as well as screening patients) and 10% in surveillance patients ([table 1)](#GUTJNL2017314005TB1){ref-type="table"}.[@R163] A number of studies have also shown that the DR for proximal SLs is 3%--13% in screening populations.[@R35] [@R51] [@R55] [@R135] [@R164]

Focussing on SSLs, the DR has been reported as 0.6%--11% in screening populations,[@R41] [@R50] [@R52] [@R57] [@R166] and 5% in an unselected population ([table 1)](#GUTJNL2017314005TB1){ref-type="table"}.[@R167] Detection rates for TSAs in screening populations has been have been shown to be \<1%.[@R50] [@R52] Three studies have reported DRs of 1%--11% for all serrated adenomas in screening populations.[@R51] [@R56] [@R164]

Other studies have investigated DRs for 'significant SLs' such as large SPs (DR 1.8%--2.3%[@R51] [@R164] in average-risk screening populations, and dysplastic/large proximal non-dysplastic SLs in an unselected population (DR 2.5%[@R125]).

Any attempt to set a benchmark for SL-DR needs to take into account that there is considerable variability in the detection rates for individual endoscopists. Results from a single-centre study of 7192 patients undergoing screening colonoscopes by 13 different endoscopists revealed that SSL detection per 100 colonoscopes ranged from 0 in the lowest detector to 2.2 in the highest detector.[@R41] The detection rate of PSLs ranged from 1% to 18% among 15 different endoscopists at the two US centres in a study of 6681 patients undergoing average-risk screening.[@R135] The results of these two retrospective studies are supported by a prospective study from the Netherlands of 1426 people undergoing colonoscopic screening; the PSP-DR ranged from 6% to 22% among five different endoscopists.[@R69]

While endoscopic skills are undoubtedly important, the detection rates for SLs are also influenced by the quality of pathology reporting. Payne *et al* have recently reported a multicentre US and German study; detection rates for SLs (defined as SSA/P, SSA with dysplasia or HPs \>1 cm in the proximal colon) ranged from 0% to 13.1% among the 32 centres, with four centres reporting no PSLs at all over the 2-year period of the study. Guidance for the pathological diagnosis of SLs has recently been published in the UK[@R37] and this will be reinforced within the updated *Reporting Lesions in the NHS Bowel Cancer Screening Programme* document that is due to be published in 2017. We envisage that these publications will help to reduce interobserver variability between pathologists during the assessment of SLs. A high-quality histology report for a SL should include the lesion type (according to the classification system in [box 2](#bx2){ref-type="boxed-text"}), size, presence and grade of any dysplasia; and proximity to the diathermy/stalk margin if this is practically possible.

The detection rate may also be influenced by ethnicity as demonstrated in a single-centre, and single endoscopist, study from Australia, which revealed that the SSL-DR was significantly higher in Caucasians when compared with Chinese (7.0% vs 2.0%).[@R167] This was also seen in a necropsy study from New Zealand.[@R42]

With the caveats mentioned above, it is clear that SLs can be detected at colonoscopy and in view of the importance of the SL pathway in the development of right-sided CRC, setting a quality standard for their detection would be an important step towards reducing the risk of proximal CRC. Kahi *et al* [@R135] have attempted to set such a benchmark for proximal SLs; based on a retrospective analysis of two colonoscopy databases, the maximum detection rate was approximately 20% in screening populations. In view of the correlation between the PSL-DR and the ADR, the authors used linear regression to model the relationship between adenoma detection and PSP detection for each endoscopist and to derive PSP detection rates corresponding to ADRs of 25% in men and 15% in women.[@R168] The PSL-DR was demonstrated to be 5% for both men and women. Recent Dutch data suggest that the PSP detection rate is strongly correlated with the clinically relevant serrated polyp detection rate (R=0.94), but less so for ADR (R=0.54), supporting PSP detection rate as a benchmark.[@R169] **Statement 14**We suggest that benchmarking SL detection rates is challenging and affected by case mix, patient ethnicity, histopathological diagnosis and the inclusion of distal SLs; however, endoscopists who wish to assess their PSP detection rate might aim for a detection rate \>5% (*weak recommendation, low quality evidence, 88% agreement*).

Research questions {#s8c}
------------------

What molecular markers predict the future malignant potential of SSPs.How can we increase accuracy and decrease interobserver variability between pathologists assessing SSPs?Which technologies and techniques will increase the detection of SLs at colonoscopy?Will intensive detection, removal and surveillance of proximal SSPs result in significant reduction in mortality from colorectal cancer and all-cause mortality.What would be the appropriate surveillance interval for proximal SSPs with and without coexisting colorectal cancer and coexisting adenomas.Is surveillance for SLs cost-effective?What chemopreventive measures would reduce the development and growth of SLs and associated cancers?What biomarkers can select patients at high risk of SLs?How can we integrate SSP into current paradigms for 'optical biopsy' at colonoscopy?How can training in recognition and resection of SLs be optimised? **Statement 15**We suggest that the current evidence base for clinical decision making for patients with SLs is poor. Clinicians are strongly advised to support prospective studies that will bolster this evidence and avoid empirical management decisions, to allow formal guidelines to be developed (*weak recommendation, low quality evidence, 100% agreement*).
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